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A B S T R A C T
The alkynyl gold(I) derivative [Au(C CPh)(PTA)] (PTA = 1,3,5-triaza-7-phosphaadamantane) induces apoptosis in
colorectal carcinoma tumour cells (Caco-2) without affecting to normal enterocytes. [Au(C CPh)(PTA)] is a slight
lipophilic drug, stable in PBS (Phosphate Buffered Saline) and able to bind BSA (Bovin Serum Albumin) by hydropho-
bic interactions. Once inside the cell, [Au(C CPh)(PTA)] targets seleno proteins such as Thioredoxin Reductase 1,
increasing ROS (Reactive Oxygen Species) levels, reducing cell viability and proliferation and inducing mitochondrial
apoptotic pathway, pro-apoptotic and anti-apoptotic protein imbalance, loss of mitochondrial membrane potential, cy-
tochrome c release and activation of caspases 9 and 3. Moreover, unlike other metal-based drugs such as cisplatin, [Au(C
CPh)(PTA)] does not target nucleic acid, reducing the risk of side mutation in the DNA. In consequence, our results
predict a promising future for [Au(C CPh)(PTA)] as a chemotherapeutic agent for colorectal carcinoma.
© 2016 Published by Elsevier Ltd.
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1. Introduction
Colorectal adenocarcinoma is one of the main causes of cancer-re-
lated death and the second most prevalent carcinoma in Western coun-
tries. The overall five-year survival is only 40% and further its inci-
dence rates are increasing in many countries [1,2]. Treatment involves
surgical resection followed by 5-fluoracil-based adjuvant therapy, but
although it substantially improves survival, it is associated with side
effects that affect overall health and quality of life [3–5]. Therefore it
is necessary to develop a novel, less toxic and more efficient therapy
to treat colorectal cancer (CRC).
Most of chemotherapeutic agents are organic molecules, but af-
ter discovering antiproliferative properties of cisplatin (cis-di-
amminedichloroplatinum(II)) [6,7], other derivatives known as sec-
ond- and third-generation analogs to cisplatin are being used in a va-
riety of cancers [8]. Despite the effectiveness of these platinum based
drugs in cancer chemotherapy, there are some drawbacks such as the
development of resistant tumour lines, long term-effects on renal func-
tion and lack of specificity [9]. This fact encourages researches to find
alternatives in order to minimize these negative side-effects. Thus,
a vast library of metal complexes have been synthesized and ana-
lyzed as anticancer agents, being the noble metals group, the most
studied [10–15]. In this context, gold-derivate drugs have recently
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emerged as new chemotherapeutic agents. Gold compounds have been
already used in medicine as antibacterial drugs, but nowadays they
are in focus thanks to the strong cytotoxicity triggered by the gold
atom in the oxidation states + 1 and + 3 in different cancer cell lines
[16–21]. Two key points make gold compounds an interesting alterna-
tive to cisplatin and its analogs: their similar chemical behavior (both
platinum(II) and gold(III) present electron configuration d8 and square
planar geometry) and its wide coordination chemistry, which allows
the synthesis of many different anticancer drugs.
Over the last decades, different types of gold-based drugs have
been reviewed in order to determinate an appropriate ligand/com-
pound combination with improved hydrophilic/lipophilic balance, op-
timized biodistribution, activity and selectivity to be chosen as a po-
tential drug in colon cancer treatment. With this idea, the use of wa-
ter-soluble phospanes like PTA (1,3,5-triaza-7-phosphaadamantane)
could improve those properties and lead to the synthesis of water sol-
uble or partially soluble complexes [22–28].
Nevertheless, despite all the investigation in gold-based drugs pub-
lished in the last years, their mechanism of action remains unclear
[29]. Gold compounds in oxidation state + 1 are classified as “soft
Lewis acids” and hence it is thought that they might target, strongly
and selectively, thiol and selenol groups of proteins [30], which are
critical to maintain the correct function of reductase proteins involved
in redox balance. This is the particular cases of glutathione system
(GSH) and thioredoxin system, which are two of the four most im-
portant antioxidant systems in most cells. The thioredoxin system,
constituted by thioredoxin (Trx), thioredoxin reductase (TrxR) and
NADPH, regulates crucial functions such as viability, proliferation
http://dx.doi.org/10.1016/j.jinorgbio.2016.11.009
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and the level of cellular hydrogen peroxide [31]. It is thought that the
selenocystein contained in Thioredoxin Reductase 1 (TrxR1) could
constitute a target for gold-based drugs [32].
Thioredoxin Reductase 1 (TrxR1) (EC:1.8.1.9), the cytosolic form
of TrxR, is an homodimeric protein codified by the gene TXNRD1.
Seven isoforms of TXNRD1 gene have been described, being iso-
form 1 the canonical sequence, which is mainly expressed in ovary,
spleen, heart, liver, kidney and pancreas, as well as cancer cells.
The active form of the enzyme contains one selenocysteine and one
FAD (Flavin Adenine Dinucleotide) group per subunit of 55 kDa and
it holds glutarredoxin and thioredoxin activity in association with
Thioredoxin protein. Both proteins contribute to redox homeostasis,
preventing and repairing damage caused by H2O2-based oxidative
stress. TrxR1 also induces the actine and tubulin polymerization. As
a consequence of redox imbalance in tumour cells, Thioredoxin and
Thioredoxin Reductase expression resulted increased in several hu-
man primary cancers and its levels are associated with aggressive tu-
mour growth and decreased patient survival [33]. Moreover, inhibi-
tion of TrxR1 with siRNA in lung cancer cells reverses their tumour
morphology and growth properties returning them to a state with sim-
ilar properties than normal cells [34]. Furthermore, TrxR1 contains a
very accessible selenocysteine on its flexible C-terminal arm which
can be modified – selectively and irreversibly – by electrophilic com-
pounds, inactivating the enzyme. In consequence, TrxR1 became an
attractive new target for cancer treatments. In particular, soft metal
ions such as platinum(II) and gold(I), can coordinate to the seleno-
cystein residue, acting as enzyme inhibitors, as has been previously
observed in cisplatin [35] and in auranofin [(1-thio-β-D-glucopyra-
nose-2,3,4,6-tetraacetato-S)(triethylphosphane) gold] [36].
The preliminary good cytotoxic properties found in alkynyl gold(I)
derivatives against A2780 ovarian cancer cells and their cisplatin-re-
sistant cell line A2780cisR [25] encouraged us to extend and deepen
antiproliferative studies in the particular case of [Au(C
CPh)(PTA)]. Thus, here we include the evaluation of the cytotoxic
activity of the gold compound towards human colon cancer cell line
Caco-2/TC7, the capacity of this complex to induce apoptosis, since
apoptosis is the predominant mechanism by which cancer cells die, its
implications in cell-cycle progression and its interactions with BSA,
nucleic acids in order to discover its mechanism of action. Finally we
include the influence of the gold(I) in the activity and expression of
two important enzymes for redox balance: TXNDR1 and GR, as well
as ROS formation. The results of this study suggest that [Au(C
CPh)(PTA)] could be used as a therapeutic approach in colorectal can-
cer treatment.
2. Experimental
2.1. Preparation of [Au(C CPh)(PTA)]
[Au(C CPh)(PTA)] was synthetized as described previously by
some of us [25]. Briefly, phenylacetylene (0.3 mmol) were added
to a solution KOH (0.385 mmol) in MeOH. After 10 min of stir-
ring [AuCl(PTA)] (0.25 mmol) was added. Then, the mixture was
stirred for ca. 20 h at room temperature; the precipitate was iso-
lated by filtration, washed twice with MeOH and dried with diethyl
ether. Yellow solid was obtained in 83% yield. 1H NMR (400 MHz,
CDCl3, 25 °C): δ 4.28 (s, 6H, NCH2P), 4.48, 4.53 (JAB = 13.3 Hz, 6H,
NCH2N), 7.20–7.31 (m, 3H, m- and p-Ph), 7.43–7.50 (m, 2H, o-Ph)
ppm. 31P{1H} NMR (CDCl3, 25 °C): δ − 51.5 ppm.
13C{1H}NMR
(CDCl3, 25 °C): δ 52.4 (d, 3C, J = 21.6 Hz, NCH2P), 63.8 (s, 1C,
AuC C), 73.3 (d, J = 7.8 Hz, 3C, NCH2N), 82.7 (s, 1C, AuC
C), 127.30 (s, 1C, p-Ph), 128.51 (s, 2C, o-Ph ), 132.4 (s, 4C, m-Ph)
ppm. Anal. Calcd. (%) for C14H17AuN3P (455.25): C 36.94, H3.76, N
9.23. Found: C 36.56, H3.39, N 9.09.
2.2. Chemical stability
The stability of the gold complex has been analyzed by absorp-
tion UV spectroscopy. UV–Vis absorption spectra were recorded on
a Thermo Scientific spectrophotometer. 20 mM solution of [Au(C
CPh)(PTA)] in DMSO (Dimethyl sulfoxide) was diluted in 10− 4 M
PBS pH = 7.4 and thereafter monitored measuring the electronic spec-
tra over 24 h at 37 °C.
2.3. Distribution coefficient (log D7.4)
N-octanol-water partition coefficient was determined by the
shake-flask method. PBS buffered distilled water (100 mL, phosphate
buffer [PO4
3 −] = 10 μM, 0.15 M NaCl, pH 7.4) and 100 mL of n-oc-
tanol shaken together for 72 h to allow saturation of both phases. Ap-
proximately 1 mg of the complex was mixed in 5 mL of aqueous and
organic phase, respectively for 10 min. The resultant emulsion was
centrifuged to separate the phases. The concentration of the compound
in each phase was determined using UV absorbance spectroscopy.
LogD7.4 was defined as log{[compound(organic)]/[compound(aqueous)]}.
2.4. Interaction with BSA
Bovine serum albumine was commercially available from Sigma
Aldrich. A1 mM stock solution of BSA was prepared in PBS at
pH 7.4. The real concentration is confirmed using UV–Vis spec-
troscopy (ε280 nm = 43,824 M
− 1 cm− 1). The gold complex was dis-
solved in dimethyl sulfoxide (DMSO) to achieve 6 mM stock solution
and six aliquots of 2.5 μL were added to a 50 μM solution of BSA in
PBS placed in a quartz cuvette of 1 cm optical path, giving rise to final
concentrations of 5, 10, 15, 20, 25 and 30 μM. The fluorescence spec-
tra were recorded on a Jobin-Yvon-Horiba fluorolog FL-3-11 spec-
trometer. The samples were excited at 295 nm and the emission spec-
tra were recorded in a range from 310 to 450 nm with emission slits set
to 1.6 nm. The samples were measure 4 min. After every addition of
the aliquots of gold complex. The fluorescence intensities of the PBS
and the gold complex were irrelevant under the described conditions,
as were the effect of addition of gold aliquots and the effect of time
incubation between measurements. The data were analyzed using the
Stern–Volmer equation F0/F = 1 + Ksv[gold complex] = 1 + Kqτ0[gold
complex] in order to obtain the Stern–Volmer quenching constant
(Ksv). The binding constant (Kb) was quantified by using the modified
Stern–Volmer equation: log{(F0 F)/F} = logKb + nlog[gold com-
plex].
2.5. Cell culture
Human Caco-2 cell line (TC7 clone) was kindly provided by Dr.
Edith Brot-Laroche (Université Pierre et Marie Curie-Paris 6, UMR
S 872, Les Cordeliers (France). Caco-2 cells were maintained in a
humidified atmosphere of 5% CO2 at 37 °C. Cells (passages 50–80)
were grown in Dulbecco's Modified Eagles medium (DMEM) (Gibco
Invitrogen, Paisley, UK) supplemented with 20% fetal bovine serum
(FBS), 1% non-essential amino acids, 1% penicillin (1000 U/mL), 1%
streptomycin (1000 μg/mL) and 1% amphoterycin (250 U/mL). The
cells were passaged enzymatically with 0.25% trypsin-1 mM EDTA
and sub-cultured on 25 or 75 cm2 plastic flasks at a density of 2 × 104
cells/cm2. Culture medium was replaced every 2 days. Cell conflu-
ence (80%), differentiated cells, was confirmed by microscopic
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observance. Experiments in undifferentiated cells were performed
24 days post-seeding.
2.6. Cell proliferation assay and IC50 values determination
Cell proliferation inhibition was measured using the MTT assay
[37]. The assay is dependent on the cellular reduction of 3-(4,5-di-
methyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide (MTT, Merck,
Darmstadt Germany) by the mitochondrial dehydrogenase of viable
cells to a blue formazan product which can be measured spectrophoto-
metrically. Caco-2/TC7 cells were plated in 96-well plates at a density
of 4000 cells per well and incubated for 24 h under standard cell cul-
ture conditions.
For IC50 values determination, a stock solution of the gold com-
plex in DMSO was added to cells in a concentration range of 0–20 μM
(10 replicates, 100 μL per well); cells treated with the same amount
of DMSO were used as negative control. Cells were exposed to the
gold complex for 24 h and then 10 μL of 5 mg/mL MTT solution were
added. Incubation was continued at 37 °C for 3 H. medium was then
removed by inversion and 100 μL of DMSO per well were added. The
solution absorbance at 560 nm, proportional to number of living cells,
was measured by spectrophotometry (DTX 800, Beckman Coulter)
and converted into percentage (%) of growth inhibition.
2.7. Propidium iodide staining of DNA content and cell cycle analysis
Caco-2/TC7 cells were exposed to IC50 of the [Au(C
CPh)(PTA)] for 24 h. Then, cells were fixed in 70% ice-cold ethanol
and stored at 4 °C for 24 h and centrifuged 5 min at 2500 rpm. Af-
ter centrifugation, cells were rehydrated in phosphate buffered saline
(PBS) and stained with 50 μg/mL propidium iodide (PI) solution con-
taining 100 μg/mL RNase A. PI-stained cells were analyzed for DNA
content in a FACSARRAY BD equipped with an argon ion laser. The
red fluorescence emitted by PI was collected using a 620 nm long pass
filter as a measure of the amount of DNA-bound PI and cell distribu-
tion was displayed on a linear scale. Cell cycle distribution was deter-
mined on a linear scale. The percentage of cells in cycle phases was
determined using MODIFIT 3.0 verity software.
2.8. Measurements of apoptosis
Caco-2/TC7 cells were exposed to IC50 of the [Au(C
CPh)(PTA)] for 24 h, then collected and stained with Annexin
V-FTIC according to the manufacturer's instructions. Untreated cells
were used as negative control, in order to define basal levels of apop-
tosis, necrosis and cell death. After incubation, cells were transferred
to flow-cytometry tubes and washed twice with temperate phos-
phate-buffered saline (PBS), resuspended in 100 μL of annexin V
binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2), then 5 μL of annexinV-FITC and 5 μL of PI was added to each
100 μL of cell suspension. After incubation for 15 min at room tem-
perature in the dark, 400 μL of 1 × annexin binding buffer was added
and analyzed by flow cytometry within one hour. The signal inten-
sity was measured using a FACSARIA BD and analyzed using FASC-
DIVA BD.
2.9. In vitro DNA binding assay
[Au(C CPh)(PTA)] was incubated at 37 °C with 3 nM
pIRES2-EGFP (5308 pb) plasmid (Catalog #6029–1). The mobility
of pIRES2-EGFP treated with the complex was analyzed by elec-
trophoresis on a 1% (w/v) agarose gel at 90 V/cm at 25 °C in Tris-ac
etate/EDTA buffer for 30 min. The gel was stained in 0.5 g/mL (w/v)
ethidium bromide and bands were visualized with UVP gel scanner.
2.10. DNA isolation
Caco-2/TC7 cells were plated in 75 cm2 flask at a density of
500,000 cells per flask, incubated for 24 h under standard cell cul-
ture conditions and then exposed to IC50 of the [Au(C CPh)(PTA)]
for 24 h. Cells were centrifuged at 3500 rpm for 5 min and pellet was
washed twice with 1 mL PBS. Then cells were lysated using 1 mL ly-
sis buffer (5 M NaCl, 1 M Tris-HCl pH 8, 0.5 M EDTA pH 8, 10%
SDS, miliQ water, 20 μL proteinase K). Resultant preparation was in-
cubated 19 h at 50–60 °C. 250 μL of 5 M NaCl were added and the
mixture was centrifuged at 13,000 rpm for 5 min. Supernatant was iso-
lated and 2 mL of ethanol 100% were added, then samples were cen-
trifuged at 10,000 rpm for 10 min. Pellet was washed with 1.5 mL of
ethanol 70% and centrifuged at 10,000 rpm for 10 min. Finally, the
pellet was resuspended in 50 μL Tris-EDTA pH 8 (TE) and heated to
40 °C for 5 min.
2.11. DNA interaction in cells
DNA of [Au(C CPh)(PTA)] treated cells was isolated as pre-
viously described. Then, DNA interactions were analyzed by
SDS-PAGE using 2% (w/v) agarose gel containing 100 μg/mL of
ethidium bromide (85 V, 45 min).
2.12. RNA isolation
Caco-2/TC7 cells were plated in 75 cm2 flask at a density of
500,000 cells per flask, incubated for 24 h under standard cell cul-
ture conditions and then exposed to IC50 of the [Au(C CPh)(PTA)]
for 24 h. After that, 650 μL of TRI Reagent® (SIGMA-ALDRICH®
9424) were added to each flask.
For RNA isolation, the obtained cell suspension with TRI
Reagent® was incubated with 130 μL of chloroform for 10 min at
room temperature. After incubation, the mix was centrifuged at
13,000 rpm for 10 min. Upper phase was collected and incubated
with 430 μL of isopropanol for 10 min at room temperature. The mix
was centrifuged again at 13,000 rpm for 15 min. The precipitate was
washed with ethanol 75%, and centrifuged at 13,000 rpm for 5 min.
The obtained pellet was dried at room temperature and hydrated with
25 μL of free-nuclease water for 2–3 h. RNA purity was checked
with polyacrylamide gel electrophoresis (SDS-PAGE) using 1% (w/v)
agarose gel containing 100 μg/mL of ethidium bromide (80 V, 1 h).
2.13. Flow cytometry mitochondrial membrane potential assay
Caco-2/TC7 cells were plated in 75 cm2 flask at a density of
500,000 cells per flask and incubated 24 h under standard cell culture
conditions. For treatment, IC50 of gold complex was added to each
flask and incubated 24 h; mock-treated cells were just incubated with
DMSO at the same concentration than treated samples. After treat-
ment, cells were washed twice with temperate PBS and then resus-
pended in temperate PBS at a concentration of 1 × 106 cells/mL. 5 μL
of 10 μM cationic dye 1,1′,3,3,3′-hexamethylindodicarbo-cyanine io-
dide (DiIC1) were added to each sample and cells were incubated
15 min at 37 °C, 5% CO2. After incubation period, 400 μL of PBS
were added to each tube and fluorescence was analyzed by flow cy-
tometry using a FACSARRAY BD equipped with an argon ion laser.
Excitation and emission settings were 633 and 658 nm, respectively.
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2.14. Determination of BAX, BCL2, caspase-3, caspase-9 and
TXNDR1 by flow cytometry
Caco-2/TC7 cells were plated in 75 cm2 flask at a density of
500,000 cells per flask and incubated 24 h under standard cell culture
conditions. For treatment, IC50 of gold complex was added to each
flask and incubated 24 h; mock-treated cells were just incubated with
DMSO at the same concentration than treated samples. After treat-
ment, cells were fixed in 0.01% formaldehyde for 15 min and cen-
trifuged for 5 min at 300 g and room temperature (RT). Then, for cell
membranes disruption, the pellet was suspended in 100 μL of 0.5%
v/v in PBS digitonin solution and incubated for 15 min in the dark at
RT. After incubation, cells were washed with 2 mL of PBS containing
0.1% digitonin and centrifuged at 300 g for 5 min. Supernatant was
discarded and pellet was resuspended in 200 μL of PBS containing
0.1% digitonin. The corresponding antibody (2 μL) was added to each
sample and the resultant mix was incubated for 1 h at RT. After incu-
bation, cells were centrifuged 5 min at 500 g at RT and washed twice
with PBS. Finally, cells were resuspended in 400 μL of PBS. Fluo-
rescence was analyzed by flow cytometry, using a FACSARRAY BD
equipped with an argon ion laser. Antibodies used for these assays and
the emission and excitation setting are listed above.
Anti-Bax antibody (Abcam [T22-A]) Ex: 493 nm, Em: 528 nm.
Anti-Bcl-2 antibody (Abcam) Ex: 645, Em 660,100 test.
Caspase 9 (active) Red Staining Kit (Ambcam) Ex: 394–400, Em:
495–505.
Anti-TXNRD1 antibody (Abcam, Alexa Fluor® 647) Ex: 652, Em:
668.
Anti-Caspase3 (Novus, Clone C92–605) Ex: 494, Em: 520.
2.15. Determination of cytochrome c by flow cytometry
Caco-2/TC7 cells were plated in 75 cm2 flask at a density of
500,000 cells per flask and incubated 24 h under standard cell cul-
ture conditions. For treatment, IC50 of gold complex was added to
each bottle and incubated 24 h; mock-treated cells were just incu-
bated with DMSO at the same concentration than treated samples. Af-
ter treatment, cytochrome c release was determined as described by
Christensen et al. [38]. Briefly, cells were resuspended in 100 μL of
ice-cold permeabilization buffer (100 mM KCl, 50 μg/mL digitonin in
PBS) and incubated for 5 min. Then, 100 μL of 4% paraformaldehyde
in PBS were added to permeabilised cells and the mixture was cen-
trifuged 5 min at 500 g at 4 °C. Supernatant was removed and the pel-
let was resuspended in 4% paraformaldehyde and incubated 20 min
at RT. After incubation, cells were washed three times in 200 μL
of PBS. The obtained pellet was resuspended in 200 μL of perme-
abilization buffer (0.05% Saponin, 3% BSA in PBS) and incubated
for 15 min at RT. Then, 2 μL of anti-cytochrome antibody (Novus
(7H8·2C12)[PE]) were added and the mix was incubated for 1 h at
RT. After incubation, cells were centrifuged 5 min at 500 g at RT and
washed twice with PBS. Finally, cells were resuspended in 400 μL
of PBS. Fluorescence was analyzed by flow cytometry using a FAC-
SARRAY BD equipped with an argon ion laser. Excitation and emis-
sion settings were 488 and 575 nm, respectively.
2.16. Intracellular peroxides (ROS) formation
The production of ROS (Reactive Oxygen Species) was assessed
using the dichlorofluorescein (DCF) assay [39]. Caco-2/TC7 cells
were plated in 96-well plates at a density of 4000 cells per well and
incubated for 24 h under standard cell culture conditions. For treat-
ment, IC50 of [Au(C CPh)(PTA)] was added to cells and incubated
24 h; mock-treated cells were just incubated with DMSO at the same
concentration than treated cells. Then, cells were washed twice with
PBS and 100 μL of 20 mM DCFH-DA (dichloro-dihydro-fluorescein-
diacetate) were added to each well. Cells were incubated 1 h at 37 °C
and washed twice with PBS; finally, 100 μL of PBS were added and
fluorescence was analyzed with DTX-880 (Beckman Counter). Exci-
tation and emission settings were 485 and 535 nm, respectively. The
intensity of fluorescence is considered as a reflection of total intracel-
lular ROS.
2.17. Thiol-reductase activity assay in cells
Caco-2 TC7 were grown in 96-well plate at a density of 4000
cells/well during 24 h, and then treated with [Au(C CPh)(PTA)]
for 24 h. After incubation time, cells were lysed with Tris-HCl buffer
(5 M NaCl, 1 M Tris-HCl pH 8, 0.5 M EDTA pH 8, SDS 10%, miliQ
water) and proteinase K and 25 μL of PBS pH 7.0 were added. Then,
25 μL of reaction mix (500 μL PBS pH 7.4, 7, 80 μL 100 mM EDTA
pH 7.5, 20 μL 0,05% BSA, 20 mM 100 μL NADPH, 300 μL distilled
H2O) were add to each well. Finally, reaction was started by adding
25 μL of 20 mM 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB, in pure
ethanol). Absorbance at 405 nm was recorded each 10 s for 6 min as a
measure of thiol-reductase activity. Thiol-reductase activity was nor-
malised by the amount of protein present in each well, determined by
Bradford method.
2.18. Glutathione reductase activity assay in cells
Caco-2 TC7 were grown in 96-well plate at a density of 4000
cells/well during 24 h, and then treated with [Au(C CPh)(PTA)]
for 24 h. After incubation time, cells were lysed with modified RIPA
buffer (50 mM Tris-HCl, 50 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 1% SDS, 1% DOC, 1 mM NaF, in miliQ water) with proteases
inhibitors. Cell solution was shaken at RT for 20 min, centrifuged for
5 min at 1200 rpm and resuspended in PBS. Then, reaction solution
was added (0.1 M Tris-HCl pH 8.1, 0.02 mM NADPH, in PBS). Fi-
nally, reaction was started by adding 0.52 mM GSSG. Absorbance at
3340 nm was recorded for 6 min. Glutathione Reductase Activity of
the cell lysate was measured as a loss in absorbance at 340 nm.
2.19. Thioredoxin reductase 1 (TrxR1) activity assay in vitro
Recombinant Human TrxR1 (SIGMA® SRP6081) was incubated
in a 96 well plate with different concentrations of [Au(C
CPh)(PTA)] complex previously dissolved in 25 μL of PBS at pH 7.4.
The cell solution was incubated in shake motion for 75 min at 37 °C.
After incubation time, 25 μL of reaction mix (500 μL PBS pH 7,
80 μL, 100 mM EDTA pH 7.5, 20 μL 0.05% BSA, 100 μL 20 mM
NADPH, 300 μL distilled H2O) were added to each well. Finally, re-
action was started by adding 25 μL of 20 mM DNTB in pure ethanol.
Absorbance at 405 nm was recorded each 10 s for 6 min as a measure
of Thioredoxin Reductase Activity.
2.20. TXNDR1mRNA quantification
TXNDR1mRNAwas quantified by qRT-PCR.
5 μg of isolated RNA were cleaned up with the commercial kit
Turbo DNA-free (Ambion AM1907). RNA integrity was analyzed af-
ter clean up by electrophoresis on a 1% (w/v) agarose gel at 90 V/
cm at 25 °C in Tris-acetate/EDTA buffer for 30 min. The presence
of protein and DNA contamination was checked in a NanodropTM
1000, (ThermoScientific). Cleaned RNA was retrotranscribed using
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the commercial kit ThermoScientific First Strand cDNA synthesis and
50 μM Oligod(T)20 primers. TXNDR1 mRNA quantification was per-
formed by qRT-PCR using the reactive Fast Start SYBR Green Master
Rox (Roche) and CXR. The primers used for qRT-PCR were 5’AAG-
GAACGCTCTCGGAATTG3’ and 5’GATAAGCCTTCAAGGTTG-
GACC3’. Gene expression modification was quantified by 2-ΔΔCt,
using cyclophiline B (PPIB) as housekeeping gene.
3. Results and discussion
3.1. Solution chemistry
[Au(C CPh)(PTA)] was isolated as a pale yellow solid in good
yield with high purity, confirmed by 1H and 31P NMR spectroscopy
(Fig. S1) and no further purification was needed.
Chemical stability under physiological conditions constitutes a
crucial characteristic of anti-tumour drugs used for treatment. Thus,
the solution chemistry of the complex was studied by absorption
UV–visible spectroscopy over 24 h at 37 °C. The complex exhibits in-
tense bands between 200 and 300 nm attributed to electronic transi-
tions from alkyne to gold(I) centre (Fig. S2). The intensity of these
bands decreased over time, probably due to a reduction of the complex
solubility. No additional bands were detected over the time and none
around 500 nm indicative of colloidal gold(0) formation. All these
findings probe that [Au(C CPh)(PTA)] is stable in PBS at 37 °C.
In addition to a solution stability, a balanced relationship between
lipophilicity and hydrophilicity results important in drug delivery
process. A potential drug should be transported in the body and pass
through membrane channels and must diffuse through the lipid por-
tion of the cell membrane. A high lipophilic character could cause
an excessive accumulation of the compound inside the cells trigger-
ing severe toxic effects, as was previously evidenced in bis-phosphine
gold(I) derivatives [40,41]. This relationship was measured in terms
of logD7.4 (n-octanol/water partition coefficient under physiological
conditions, pH 7.4). LogD7.4 obtained for [Au(C CPh)(PTA)] was
0.40, revealing a slight lipophilic character of the complex.
3.2. Interaction with BSA
Serum albumins are one of the most studied molecules as model
proteins in drug-protein interaction studies. In addition, they play an
important role in the transport and deposition of the drugs to its targets
[42,43]. Bovine serum albumin (BSA) is one of the most used proteins
and presents 76% sequence identity with the human albumin (HSA)
[44]. Most of drugs bond reversibly to serum albumin and then the
drug-protein complex is transported through the blood stream. More-
over, the nature and force of this protein-drug interaction influence the
biological activity of the drug and its pharmacodynamics. This inter-
action is especially important for lipophilic drugs as the gold complex
under study [Au(C CPh)(PTA)].
It has been demonstrated that binding to serum albumin can in-
hibit delivery and limit drug efficacy [45], and structural studies have
identify the hydrophobic regions in serum albumin as the specific
binding site [46]. In consequence, we decided to study the capacity
of [Au(C CPh)(PTA)] to interact with BSA and the nature of that
binding. BSA comprises of a chain of 580 amino acids residues with
a well-known structure consisting of a single peptide chain that con-
tains two tryptophans, Trp-134 and Trp-212, which possess intrinsic
fluorescence [47]. This amino acid is sensitive to its local environ-
ment, consequently any changes observed in its fluorescence emis-
sion spectra could indicate a possible conformational change or bind
ing to a substrate. The interaction of [Au(C CPh)(PTA)] with BSA
has been quantified by the measure of the fluorescence of BSA in
the range of 310–450 nm upon excitation at 295 nm and in the pres-
ence of varying concentrations of the complex. As can be observed in
Fig. 1, there is a decrease in the fluorescence intensity as a function
of increasing concentration of the gold complex. The corresponding
fluorescence quenching data were analyzed to obtain the quenching
constant Ksv by using the Stern–Volmer equation F0/F = 1 + Ksv[com-
plex], where F0 and F are the fluorescence intensities at 350 nm in the
absence and presence of [Au(C CPh)(PTA)] (Table 1). After plot-
ting Fo versus [complex] the slope gives the value of Ksv (Fig. 2A). We
studied the interaction with BSA at different temperatures (see below)
in order to elucidate the possible mechanism.
Determination of the binding constant in the case of interaction of
small molecules with macromolecules can be afforded by the modified
Stern–Volmer equation (double logarithm regression curve: log{(F0
F)/F} = logKb + nlog[complex]). The equation gives the binding
constant (Kb) or the apparent association constant for complex-pro-
tein interaction and the number of binding sites (n) (see Table 1).
Both parameters can be deduced from the intercept and slope, re-
spectively, by plotting log{(F0 F)/F} versus log[complex] (Fig. 2B).
The value obtained in the experiment for the binding constant at
room temperature of 7.21·104 M− 1 is notably higher than the mea-
sured in the interaction of cisplatin with HSA 8.52·102 M− 1 [48] and
in related alkyne gold(I) derivatives (values ranging from 101 to 103)
[49], but is next to the values found in the anion [Au(CN)2]
− [50]
and in gold(III) complexes (104–105) [51,52], although significantly
smaller than the observed in gold nanoparticles (around 108–1010)
[53,54]. The experimental value of Kb of 7.21·10
4 M− 1 is in accor-
dance with a significant interaction with BSA, which would allow the
biodistribution of the drug in plasma. A weak binding gives higher
drug concentration in plasma leading to a poor distribution of the
Fig. 1. Fluoresce quenching of BSA in presence of increasing concentration of [Au(C
CPh)(PTA)] at 295 K.
Table 1
Values of quenching constant (Ksv), apparent binding constant (Kb), binding sites (n)
and thermodynamic parameters for BSA interaction with [Au(C CPh)(PTA)] at dif-
ferent temperatures.
T (K) n
Ksv(L mol
− 1)
(× 104) Kb(M
− 1)
ΔGo
(KJ mol− 1)
ΔHo
(KJ mol− 1)
ΔSo
(J mol− 1 K− 1)
295 1.09 2.9 7.21·104 -27.60 161.13 639.76
304 1.34 1.75 6.38·105 -33.36 161.13 639.76
310 1.44 1.61 1.66·106 -37.20 161.13 639.76
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Fig. 2. (A) Stern–Volmer plot for the quenching of BSA with [Au(C CPh)(PTA)] at 295 K. Stern–Volmer equation used: F0/F = 1 + Ksv[complex]. The slope of the best fit linear
trend provides the Stern–Volmer quenching constant Ksv. (B) Stern–Volmer plot for the quenching of BSA with [Au(C CPh)(PTA)]. Stern–Volmer equation used: log{(F0 F)/
F} = logKb + nlog[complex]. The intercept of the best fit linear trend provides the binding constant Kb.
drug, while a strong interaction could improve the distribution and
drug pharmacological effect. [55].
A linear Stern–Volmer plot (Fig. 2A) is in accordance with the
presence of a single type of quenching mechanism, either static or dy-
namic [56]. A dynamic quenching is due to collisions between the
quenching agent and the fluorophore (BSA in our experiment) and in
a static quenching, the quenching agent forms a non-flourescent com-
plex with the fluorophore. Dynamic mechanism depends upon diffu-
sion, which increases with the temperature, consequently the quench-
ing constant Ksv, is expected to increase with the temperature. Table
1 displays the values of Ksv at three temperatures. The results indi-
cate that the Stern–Volmer quenching constant is inversely correlated
with temperature, which is agreement with the formation of a com-
plex of the quencher with BSA (static mechanism) [56]. Dynamic or
static mechanism can be distinguished by an UV–vis absorption ex-
periment. Collisional quenching only modifies excited states and con-
sequently there should be no changes in the absorption spectra. Con-
versely, ground-state complex formation (static quenching) frequently
results in the presence of modified UV–vis spectrum [57]. The ab-
sorption spectra of BSA in the presence and in the absence of [Au(C
CPh)(PTA)] at the same concentration at room temperature are
recorded in the supplementary material (Fig. S8). A mathematical su-
perposition of the BSA spectrum and the gold derivative spectrum was
calculated. The calculated superposition and the corresponding spec-
trum of BSA in the presence of the gold derivative displays a devia-
tion in the superposition pointing out to a static mechanism as a conse-
quence of a BSA-[Au(C CPh)(PTA)] complex formation, which is
in accordance with the results derived from Ksv data at different tem-
peratures.
The interaction forces between small molecules and biomolecules
include hydrogen bonds, van der Waals forces, electrostatic and hy-
drophobic attraction [58]. In the study of those interactions, the deter-
mination of the sign of the thermodynamic parameters ΔG°, ΔH° and
ΔS° is critical. These data were calculated with the van't Hoff equa-
tion Kb = − ΔH
o/RT + ΔSo/R, where Kb is the binding constant calcu-
lated at different temperatures and R is the gas constant. The value
of enthalpy exchange ΔHo is calculated from the slope of the plot of
ln Kb vs. 1/T (Fig. S7, supplementary material) and the free energy
change ΔGo is estimated from the relationship ΔGo = ΔHo − T ΔSo.
In this case, the values of ΔH° > 0 and ΔS° > 0 (Table 1) are indica-
tive of the existence of hydrophobic interactions between [Au(C
CPh)(PTA)] and BSA and ΔG° < 0 supports the presence of a spon-
taneous process. These results correlates with the slight lipophilic na-
ture of [Au(C CPh)(PTA)]. Finally, the number of binding sites (n)
increases with temperature (Table 1) revealing a dynamic component
in the binding between [Au(C CPh)(PTA)] and BSA.
3.3. Antiproliferative activity
The cellular effects of [Au(C CPh)(PTA)] have been tested
against human colon cancer cell line Caco-2/TC7. This cell line, de-
rived from human colon adenocarcinoma, is considered one of the
most regular used for intestinal drug absorption studies. It undergoes
spontaneous enterocytic differentiation when cultured over confluence
for 21 days to become polarized cells expressing apical and basolat-
eral surfaces with well-established tight junctions. So, we investigated
the influence of [Au(C CPh)(PTA)] on the growth and proliferation
of Caco-2/TC7.
At first, we investigated the cellular effects of [Au(C
CPh)(PTA)] on undifferentiated Caco-2/TC7. Antiproliferative effects
-expressed in terms of IC50 values- were observed after exposure to the
drug for 72 h, using the well-established MTT assay. The correspond-
ing IC50 value calculated of 2.65 ± 1.1 μM indicates a strong cytotoxic
activity of the gold complex.
We compared the effect of [Au(C CPh)(PTA)] on normal ente-
rocytes (Caco-2/TC7 cells under confluence) and also on cancer cells
(Caco-2/TC7 cells which not have reached confluence) to predict its
behavior on a real colon [59]. We observed a significant reduction in
proliferation of 78% in cancer cells (Fig. 3) while this reduction was
absent in normal cells where cell viability was over 91%. MTT as
Fig. 3. Cell viability of Caco-2/TC7 cell line upon treatment with 2.65 μM [Au(C
CPh)(PTA)]. Gold complex treatment reduced cancer cells viability in a 78.4% com-
pared to control cells, whereas it does not affect the viability of differentiated entero-
cytes. Data are presented as % of viability compared to control group ± standard error
of 16 independent experiments. *p < 0.01. (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
UN
CO
RR
EC
TE
D
PR
OO
F
Journal of Inorganic Biochemistry xxx (2016) xxx-xxx 7
says revealed that [Au(C CPh)(PTA)] can stop the uncontrolled
proliferation of cancer cells without affecting normal enterocytes; so
it appears to selectively target cancer cells.
3.4. [Au(C CPh)(PTA)] induces apoptosis in cancer cells
Since [Au(C CPh)(PTA)] treatment proved to reduce cell via-
bility, we hypothesized that it could induce apoptosis on Caco-2/TC7
cells. To address this hypothesis, we performed flow cytometry analy-
sis of annexin V/propidium iodide-stained Caco-2/TC7 cells. During
the early stages of apoptosis, the cell membrane loses asymmetry and
the membrane phospholipid phosphatidylserine is translocated from
the inner to the outer part of the membrane. Annexin-V (FITC con-
jugated) specifically binds to phosphatidylserine and can be detected
by flow cytometry, thereby allowing the identification of early stage
apoptotic cells. Viable cells with intact membranes and cells undergo-
ing early apoptosis but with relatively intact membranes exclude pro-
pidium iodide, whereas the membranes of dead and damaged cells are
permeable to PI and are also stained with annexin-V.
The cell-state distributions after 24 h treatment with [Au(C
CPh)(PTA)] showed a trong antiproliferative effect in comparison to
the control (Fig. 4 and Table 2) on undifferentiated cells. Late apop-
totic cell population was higher than positive control (staurosporine)
and even higher than early apoptotic events (control-butyrate). Only
negligible populations of necrotic cells were detected. (See Table 3.)
We also examined whether [Au(C CPh)(PTA)] could induce
apoptosis on normal enterocytes using low cytometry analysis of an-
nexin V/propidium iodide-stained Caco-2/TC7 cells which have
reached confluence. Significant number of viable cells were present
after 24 h of incubation with [Au(C CPh)(PTA)], similar to the
control (Fig. 4 and Table 2). Again, an increase of necrotic events was
not observed.
Chemotherapy-induced apoptosis results very interesting [60]
since necrosis can cause various side effects including septic shock
and kidney failure that may compromise patient health. In light of this,
it is important to notice the absence of necrosis observed. These apop-
tosis analysis pointed out once again the apparent selectivity of the
compound, as it was previously shown in the MTT assay.
3.5. Role of caspases, pro-apototic and anti-apoptic proteins in
[Au(C CPh)(PTA)]-induced apoptosis
Once apoptosis has been proposed as the cell death mechanism in-
duced by [Au(C CPh)(PTA)], we investigated the role of different
caspases, pro-apoptic and anti-apototic proteins in such induced apop-
tosis. It is already known that anti-apoptotic proteins, such as BCL-2
(B-Cell Lymphoma 2) protect the cell from cytochrome c translo-
cation [61], whereas pro-apoptotic proteins, such as BAX, promotes
the permeabilization of the outer membrane of the mitochondrion and
hence the efflux of cytochrome c [62]. In the cytoplasm, cytochrome
c associates with Apoptosis Protease-Activating Factor-1 (APAF-1)
and induces the activation of pro-caspase 9 via proteolytic cleavage
[63]. Later, caspase 9 will activate caspase 3, an executioner protein
of apoptosis [64].
Firstly, we used flow cytometry to analyze the influence of [Au(C
CPh)(PTA)] in the levels of the BAX and BCL-2. Cells treated
with [Au(C CPh)(PTA)] for 24 h showed a 1.6-fold increase in
BAX levels (Fig. 5A and Fig. S9) and a 5.2-fold decrease in BCL-2
levels (Fig. 5B and Fig. S9), demonstrating that [Au(C CPh)(PTA)]
can disrupt the balance between pro-apoptotic and anti-apoptotic pro-
teins. In Caco-2/TC7 cells this balance disruption is mainly caused
by a reduction of anti-apoptotic proteins rather than an
increase of pro-apoptotic signals. Caco-2/TC7 cells, as many colon
tumors, harbor mutations in TP53 [65], a protein responsible for the
up-regulation of BAX expression [66]. In consequence, the mutation
E204X of TP53 present in Caco-2/TC7 cell line [65] might affect its
capacity to bind DNA and induce BAX expression. Nevertheless, it
seems that the decrease of BCL-2 levels is sufficient for apoptosis in-
duction in Caco-2/TC7.
The next analyzed step of mitochondrial apoptotic pathway is the
alteration of mitochondrial membrane potential (MMP). MMP is gen-
erated and maintained by concentration gradients of ions such as
sodium, potassium, chloride, and hydrogen. During apoptosis, an un-
controlled production of oxygen radicals, as well as a disruption of
the pro-apoptotic vs. anti-apoptotic protein balance, stimulates Ca2 +
release from mitochondria, and hence Ca2 + cycling. Successively,
Ca2 + cycling causes mitochondrial uncoupling, ATP depletion, alter-
ation of mitochondrial potential and massive disturbance of cellular
Ca2 + homeostasis, which stimulates Ca2 +-dependent endonuclease(s)
[67]. Therefore, we analyzed the possible changes in MMP by us-
ing the cationic dye DilC1(5) (1,1′,3,3,3′-hexamethylindodicarbo-cya-
nine iodide) and flow cytometry. As it was expected, we found a
decrease of MMP in cells treated with [Au(C CPh)(PTA)] com-
pared with control cells (Fig. 6A). These results could indicate that
[Au(C CPh)(PTA)] dependent reduction of BCL-2 levels is suf-
ficient to reduce MMP, which is considered as a sign of apoptosis
[68]. On the other hand, we observed an increase in the mean fluores-
cence of [Au(C CPh)(PTA)] treated cells with positive MMP com-
pared to control (Fig. 6B, S9). MMP is generated by a proton gra-
dient across the mitochondrial inner membrane created by the oxida-
tion of substrates. The gold atom contained in [Au(C CPh)(PTA)]
could be able to interact with different molecules inside the cell, and
also inside the mitochondrion, increasing ROS production and en-
hancing mitochondrial proton gradient which will result in an increase
of MMP. However, when the concentration of ROS reaches a limit,
different mitochondrial structures can get damaged such as mitochon-
drial DNA, lipids and proteins. In particular, ROS target the mitochon-
drial Permeability Transition Pore (mPTP). mPTP is a multiprotein
complex whose core constituted by voltage-dependent anion channel
(VDAC), ANT (adenine nucleotide translocator), and cyclophilin D
localized in the outer, inner mitochondrial membrane, and mitochon-
drial matrix respectively. Oxidation of ANT critical thiol group in
Cys160 and Cys257 induces opening of the mPTP. Oxidative modifi-
cations of mPTP proteins – induced by ROS or Ca2 + among others –
modify mitochondrial anion fluxes and mPTP reaches a high-conduc-
tance state, which deregulate the entry of small solutes into the mi-
tochondrial matrix. This phenomenon is called mitochondrial perme-
ability transition (MPT) and results in immediate dissipation of the
mitochondrial membrane potential, osmotic swelling of the mitochon-
drial matrix and collapse of MMP [69]. These evidences suggest that
those cells with high MMP could remain in MPT which will be end up
in MMP reduction and apoptosis induction.
As we have introduced before, disruption of MMP is tightly re-
lated to apoptosis. Decrease in MMP – as we have observed in the
study – induces structural changes in mitochondria such as matrix
condensation and crests unravelling. These structural changes result
in the redistribution of cytochrome c from the inner membrane to
the intermembrane space, making it more susceptible to be released
[70]. With the aim to discover whether our complex was able to in-
duce mitochondrial permeabilization and cytochrome c release, we
used flow cytometry to analyze cytochrome c levels in treated and
untreated cells. The results of the experiment showed that [Au(C
CPh)(PTA)]-treated cells contained a 23% less of mitochondrial cy-
tochrome c compared to control cells. As the total amount of cy
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Fig. 4. Apoptosis analysis of Caco-2/TC7 cell line upon treatment with 2.65 μM [Au(C Ph)(PTA)]. The gold derivative induces an increase of apoptotic events in undifferentiated
Caco-2/TC7 cells (cancer cells) (A) compared to control cells (B) whereas it does not significantly induce apoptotic events in differentiated Caco-2/TC7 cells (enterocytes) under
[Au(C CPh)(PTA)] treatment (C) compared to control (D). Positive controls for early and late apoptosis were performed by using 20 mM butyrate for 16 h (E) and 1 μM stau-
rosporine for 60 min (F) treatment respectively. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
tochrome c should be similar in both conditions, a decrease of mito-
chondrial cytochrome c implies a release of this protein from the mi-
tochondria to the cytoplasm (Fig. 7 and Fig. S9).
Once cytochrome c is released to the cytoplasm, it could bind to
and activate the Apoptosis Protease-Activating Factor-1 (APAF-1).
Afterwards, the gold complex will bind to ATP/dATP, constituting the
apoptosome, which will mediate the activation of caspase-9 by prote-
olytic cleavage of pro-caspase 9 [71]. Levels of active caspase-9 were
determined by flow cytometry in complex-treated cells and compared
with those in control cells. Our results showed a slight increase of
1.13-fold of active caspase-9 levels in treated cells compared to con-
trol cells (Fig. 8A). Although this results suggest that [Au(C
CPh)(PTA)] do not induce a high activation of caspase-9 in the first
24 h after treatment, we investigate whether this increase in the levels
of active caspase-9 could be sufficient for the execution of apoptosis.
The last step in the intrinsic apoptosis pathway is the activation of
the effector caspases such as caspase-3. Caspase-3 is activated by a
proteolytic cleavage induced by initiator caspases. In this process we
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Table 2
Apoptotic percentages of Caco-2/TC7 cell line upon treatment with 2.65 μM
[Au(C = CPh)(PTA)]. Summary of differentiated (enterocytes) and undifferentiated
Caco-2/TC7 cells (cancer cells) treated with [Au(C = CPh)(PTA)] and compared with
negative control (untreated cells), and positive controls for early apoptosis (20 mM bu-
tyrate for 16 h) and late apoptosis (1 μM staurosporine for 60 min).
Cells Treatment
Live
(%)
Early
apoptosis
(%)
Late
apoptosis
(%)
Necrosis
(%)
Undifferentiated Negative
control
78.89 5.84 11.78 2.5
Undifferentiated Butyrate 55.85 32.11 11.75 0.29
Undifferentiated Staurosporine 43.34 15.49 40.7 0.47
Undifferentiated [Au(C
CPh)(PTA)]
43.62 4.65 48.66 3.07
Differentiated Negative
control
66.0 16.3 15.9 1.7
Differentiated [Au(C
CPh)(PTA)]
72.86 2.78 15.53 8.83
Table 3
Thiol-reductase activity in Caco-2 cell lysates. The thiol-reductase activity was mea-
sured as the increase of absorbance at 412 nm per minute in the regular DTNB assay
and corrected by the total amount of protein present in the cell lysate. Values in paren-
thesis represent the percentage of activity related to control (*P < 0.05).
Condition Thiol-reductase activity (μmol mg− 1 min− 1)
Control 0.150 ± 0.029 (100%)
[Au(C CPh)(PTA)] 0.130 ± 0.014 (85.84%)*
would like to highlight the role of caspase-8 and -9 which connect
with the extrinsic and intrinsic apoptotic pathways respectively [71].
Once capase-3 has been activated, it induces the proteolytic cleavage
of a large number of essential proteins for apoptosis [72]. Due to the
key role of caspase-3 in both extrinsic and intrinsic apoptotic path-
ways, we analyzed the levels of capase-3 in [Au(C CPh)(PTA)]
treated cells by flow cytometry. We found a 1.5-fold increase of cap-
sase-3 levels in treated cells compared to control (Fig. 8B and Fig.
S9). This increase in active capase-3 seems to be sufficient for apop-
tosis induction in Caco-2/TC7 cells. Moreover, this results suggest
that the slight increase of active caspase-9 levels found in [Au(C
CPh)(PTA)] treated cells could be sufficient for initiating the apop-
totic process, although the participation of other apoptotic pathways
cannot be discarded.
Consequently, our results suggest that [Au(C CPh)(PTA)] dis-
rupts the balance of anti-apoptotic versus pro-apoptotic proteins by
decreasing anti-apoptotic proteins levels and inducing mitochondrial
permeability transition (MPT) which alters mitochondrion permeabil-
ity and triggers MMP reduction as well as cytochrome c release. These
alterations promote the activation of the caspase cascade that culmi-
nates in the execution of apoptosis.
3.6. Cell cycle modification
Since cell proliferation was inhibited by [Au(C CPh)(PTA)],
we investigated whether this compound could induce a sort of alter-
ation of cycling-dependent kinases. Previous studies from Li et al.
[73] showed that some chemotherapeutics could reduce cyclin B1 and
Cdc1 expression and increase p53, p21waf1/cip1, p27kip1 and Gad-
d45 transcription, which produce an arrest in phase G2-M. Those mod-
ifications in protein expression could be promoted by an increase in
ROS levels [74].
Fig. 5. Characterization of [Au(C CPh)(PTA)]-induced apoptosis by flow cytometry in Caco-2/TC7 cells. Quantification by flow cytometry of (A) pro-apoptotic protein BAX,
(B) anti-apoptotic protein BCL-2. Results are expressed in mean arbitrary units.
Fig. 6. Characterization of [Au(C CPh)(PTA)]-induced apoptosis by flow cytometry in Caco-2/TC7 cells. Quantification by flow cytometry of (A) number of cells with positive
MMP, (B) mean MMP per cell. Results are expressed in arbitrary units.
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Fig. 7. Quantification of mitochondrial cytochrome c by flow cytometry in [Au(C
CPh)(PTA)]-treated Caco-2/TC7 cells. Results are expressed as arbitrary fluorescence
units.
Cell cycle analysis of cancer cells treated with [Au(C
CPh)(PTA)] showed a reduction of the events on G2 (Fig. 9B), which
is consistent with the reduction of cell proliferation triggered by this
compound. Nevertheless, results in differentiated Caco-2/TC7 cells
showed that [Au(C CPh)(PTA)] does not affect to cell cycle of nor-
mal enterocytes (Fig. 9D), another proof of the apparent selectivity of
[Au(C CPh)(PTA)] in cancerous cells.
3.7. Interaction with nucleic acids
DNA has been identified as one of the main targets for most of
the current drugs employed in advanced clinical trials. Some metal
based anticancer drugs interact with nucleic acids by covalent bind-
ing and/or intercalation, being the platinum like metallodrugs the most
known examples [75,76]. However the occurrence of several disad-
vantages, that includes important side effects and intrinsic or acquired
resistance, from the use of cisplatin and its analogs, has favored the
development of new cytotoxic metallodrugs with DNA independent
mechanism of action [77,78].
To analyze DNA integrity and to detect a possible interaction be-
tween [Au(C CPh)(PTA)] and nucleoids, we firstly analyzed the
reactivity of [Au(C CPh)(PTA)] complex and the plasmid
pIRES2-EGFP (5308 pb) in vitro. The SDS-PAGE showed that treat-
ment with increasing amounts of the gold complex does not affect
the mobility of the plasmid, conversely with the observed in cisplatin
that is in accordance with the lack of interaction with the plasmid
pIRES2-EGFP (DNA) (Fig. S10).
Then, the reactivity of [Au(C CPh)(PTA)] with DNA was eval-
uated in cells. We isolated DNA from Caco-2/TC7 cells treated with
the gold complex for 24 h and then agarose gel electrophoresis study
was performed (Fig. 10A). DNA electrophoresis revealed a single
band in each condition with a similar molecular weight to negative
control, suggesting that [Au(C CPh)(PTA)] did not form mono
adducts with DNA as cisplatin does [79].
Likewise, DNA electrophoresis showed an absence of the inter-
nucleosomal fragmentation and a DNA ladder pattern ˗one of the
main biochemical hallmarks of apoptosis [80] — in [Au(C
CPh)(PTA)]-treated cells (Fig. 10A), neither it could be detected in
our positive controls for apoptosis, butyrate and staurosporine (Fig.
10B). These results correlate with the absence of DNA fragmentation
in some cell lines as Caco-2/TC7, where this ladder pattern cannot be
seen [81]. When a cell dies through apoptosis, its chromatin is con-
densed and then broken into internucleosomal fragments by endonu-
cleases like DF40, which is activated by caspase-3. This fragmenta-
tion takes place in a later steps of apoptosis, so is absent, joined to
the results of caspases activation obtained by flow cytometery, might
indicate that analyzed Caco-2/TC7 remained in the early stage of the
process [82]. Deficiencies in DF40 could also explain the absence of
the ladder pattern obtained in our SDS-PAGE.
Cisplatin is also capable of binding RNA and preventing its trans-
lation to proteins [83]. Nevertheless [Au(C CPh)(PTA)] did not
display any interaction as can be deduced from SDS-PAGE elec-
trophoresis studies of the total RNA isolated from Caco-2/TC7 cells
treated with the gold derivative, confirming the initial hypothesis of
a different mechanism of action. We observed three different bands
corresponding to 28S rRNA, 18S rRNA and tRNA without degrada-
tion or retardation in their migration (Fig. 11). Again, dissimilarities at
atomic level between gold and platinum may explain the inability of
[Au(C CPh)(PTA)] to interact with RNA as cisplatin does.
3.8. Effects on ROS formation
As our previous results in flow cytometry report, mitochondria
seems to be altered by the treatment with [Au(C CPh)(PTA)]. Con-
sidering that this organelle is a natural source of ROS, and having
into account that ROS generation may be a cause or even a conse-
quence of the mitochondrial permeability transition pore opening and
mitochondrial alterations in apoptosis [84], we consequently studied
ROS formation in Caco-2/TC7 cells in response to gold treatment
after 24 h using the fluorogenic freely permeable tracer DCFH-DA.
Our results showed that [Au(C CPh)(PTA)] induced a notable in-
crease in ROS production of 1.22-fold compared to mock-treated cells
(Fig. 12); increase which was even higher than the obtained with
Fig. 8. Quantification of caspases by flow cytometry in control and gold complex treated Caco-2/TC7 cells. (A) Active caspase-9 and (B) active caspase-3. Results are expressed as
arbitrary fluorescence units. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 9. Cell cycle analyses in differentiated (enterocytes) and undifferentiated Caco-2/TC7 cells (cancerous cells). Treatment with [Au(C CPh)(PTA)] complex induced an in-
crease of G2 events in undifferentiated cells (B) compared with control (A), whereas cell cycle of normal enterocytes treated with [Au(C CPh)(PTA)] (D) was not significantly
affected compared to cell cycle of untreated differentiated caco-2/TC7 cells (C).
Fig. 10. Interaction between nuclear DNA of Caco-2/TC7 cells and [Au(C
CPh)(PTA)]. Electrophoresis of Caco-2/TC7 nuclear DNA. (A) Line 1 untreated cells;
lines 2–3 2.65 μM [Au(C CPh)(PTA)]-treated cells. (B) Positive controls for apop-
tosis: line 4 cell treated with staurosporine; line 5 cells treated with butyrate.
cells treated with the well-known gold based antirheumatic drug aura-
nofin. This increase in ROS levels triggered by gold (I) atoms corre-
lates with the finding published previously in the literature [85–87].
3.9. Thiol-reductase activity in cell lysates
The results obtained in ROS determination lead us to postulate a
modification of redox-defences as an hypothetical action mechanism
Fig. 11. Interaction between RNA and [Au(C CPh)(PTA)]. RNA electrophoresis of
Caco-2/TC7 cells untreated (line 1) and after 2.65 μM [Au(C CPh)(PTA)] treatment
(line 2). RNA integrity is maintained in both cases. No signs of interaction between
RNA and [Au(C CPh)(PTA)] could be detected.
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Fig. 12. Quantification of ROS by DCFH-DA method 80 min. DCFH-DA fluoresce
at 80 min showed higher levels of total intracellular ROS in cells under [Au(C
CPh)(PTA)] treatment than those for negative – mock treated cells – and positive – au-
ranofin treated cells – controls. Results are expressed in arbitrary units. (**P < 0.005;
***P < 0.001).
for [Au(C CPh)(PTA)] complex. Reactive oxygen species produc-
tion in cells is inevitable, however an excessive ROS production is
considered harmful to cells. There are some enzymatic and non en-
zymatic antioxidant systems able to neutralize ROS, such as the glu-
tathione (GSH) and thioredoxin (Trx) systems. In this context, Thiore-
doxin reductase (TrxR) together with Glutathion reductase (GSR),
with selenocysteine and cysteine active sites, respectively, provide
reducing equivalents needed in many cellular processes. As stated
above, gold(I) which is defined as a ‘soft’ acid , has strong affinity
for ‘soft’ bases such as selenium and sulphur containing molecules.
Consequently gold(I) derivatives can be considered as potential en-
zyme inhibitors [32]. Since most of the antioxidant defences are based
on the presence of sulfhidryl groups, we firstly investigate the capac-
ity of [Au(C CPh)(PTA)] complex to modify the levels of total re-
duced thiol groups and hence to inhibit the thiol reductase activity
in cell lysates using a colorimetric assay. Our results showed a de-
crease of the thiol-reductase activity in treated cells lysate compared
to mock-treated control.
3.10. Glutathione reductase and thioredoxin reductase activity
As we have previously mentioned, Thioredoxin reductase and Glu-
tathione reductase are two of the most important cell systems respon-
sible for the maintenance of ROS balance and its activity depend
on the presence of a reduced sulphydryl group. In consequence, we
determined whether this reduction of thiol reductase activity in cell
lysates triggered by [Au(C CPh)(PTA)] could affect to the activity
of Thioredoxine reductase and Glutation reductase.
Our results showed that [Au(C CPh)(PTA)] was able to inhibit
TrxR1 activity in vitro in a dose-dependent manner (Table 4) whereas
Glutation reductase activity did not result reduced, on contrary a
slightly increase in its activity was detected, probably induced by the
increase in ROS species triggered by [Au(C CPh)(PTA)] (Table 5).
The capability of [Au(C CPh)(PTA)] to reduce TrxR but not GSR
activity in cells can be explained by the differences found in the active
sites of both enzymes. The redox active site of TrxR consist on a se-
lenylsulfide/selenothiol motif localized in the C-terminal tetrapeptide
-Gly-Cys-Sec-Gly-COOH which receives the electrons from another
redox-active site -Cys-Val-Asn-Val-Gly-Cys- present in the N-ter-
minal domain of the paired subunit of the active dimer. This se-
lenylsulfide/selenothiol motif localized in the C-terminal results eas-
ily accessible for drugs, allowing [Au(C CPh)(PTA)] to target the
selenocystein present in this group, inhibiting its enzymatic activ
Table 4
Inhibitory effects of [Au(C CPh)(PTA)] on Thioredoxin reductase 1 (TrxR1) at IC50
and 2xIC50 concentrations. TrxR activity was measured as the increase of absorbance at
412 nm per minute. Values are given as mean ± SD of nine independent experiments.
Values in parenthesis represent the percentage of activity related to control.
Conditions Specific TrxR1 activity (μmol mg− 1 min− 1)
Control 0.296 ± 0.032 (100%)
[Au(C CPh)(PTA)] 0.215 ± 0.028 (72.63%)
⁎
[Au(C CPh)(PTA)] (2 ×) 0.192 ± 0.024 (64.86%)
⁎⁎⁎
⁎ P < 0.05.
⁎⁎⁎ P < 0.005.
Table 5
Glutathione reductase activity of Caco-2 cell lysates. Glutathione reductase activity was
measured as the NADPH consumption, which was determined by the reduction of ab-
sorbance at 340 nm per minute. Values are given as mean ± SD of nine independent
experiments. Values in parenthesis represent the percentage of activity related to con-
trol (*P < 0.05).
Condition Glutathione Reductase Activity (nmol·min− 1)
d 1.552 ± 0.332
[Au(C CPh)(PTA)] 1.748 ± 0.529 (112.67%)
ity [88]. On the other hand, GSR lack of this a selenylsulfide/se-
lenothiol motif and in consequence the access of drugs in general,
and [Au(C CPh)(PTA)] in particular, to the active centre might be
hamper, impeding drug inhibition. The inhibition of TrxR activity has
been also found in different alkynyl gold(I) derivatives reported previ-
ously [89–93]. These results suggest a selectivity of gold alkynyl com-
pounds towards TrxR over other related enzymes such as GSR, as it
was previously described in the literature by Meyer et al. [93].
3.11. Thioredoxin reductase expression
Finally, we investigated if [Au(C CPh)(PTA)] treatment could
affect not only TrxR activity but also its expression. We firstly an-
alyzed by qRT-PCR the effects of [Au(C CPh)(PTA)] in Thiore-
doxin reductase 1 (TXNRD1) and Thioredoxin (TXN) mRNA expres-
sion. We found that the inhibition of TXNRD1 triggered by [Au(C
CPh)(PTA)] induces an increase of both TXNDR1 and TXN expression
in tumour cells, being the more exacerbate the first one (Fig. 13).
Then, we wanted to corroborate whether those changes in TXN-
RD1mRNA were translated at protein levels. To achieve this aim, we
analyzed the levels of TXNRD1 in mocked and [Au(C CPh)(PTA)]
treated cells by flow cytometry, finding a 1.35-fold increase of TXN-
DR1 protein quantity in treated cells compared to control cells (Fig.
14).
The regulation of TrxR1 activity in cells involves a complex inter-
action of many different factors which act at different genetic levels.
TXNRD1 transcription is controlled by a strong promoter that ensures
high constitutive levels of TXNRD1mRNA. This mRNA harbours a
3′ untraslated Adenylate-Uridylate-rich elements (AREs) which regu-
lates its stability. Under normal conditions, TXNRD1mRNA lifetime
is very short, but, upon different stimuli – such as an increase in ROS
triggered by TrxR1 inhibition itself – ARE motif stabilizes TXNRD1
mRNA, enabling a quick increase in TrxR1 protein levels [94,95].
Nevertheless, this newly synthetized TrxR1 is rapidly inactivated by
[Au(C CPh)(PTA)] and the exacerbated ROS levels present in-
side the cell. In consequence, although cells are able to unregulated
their ROS defences to fight against [Au(C CPh)(PTA)] they cannot
manage their internal ROS levels, and hence mitochondrial apoptotic
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Fig. 13. TXN and TXNRD1 expression in cancer cells and normal enterocytes under [Au(C CPh)(PTA)] treatment. 2.65 μM [Au(C CPh)(PTA)] treatment induces TXN (A)
and TXNRD1 (B) transcription demonstrated by qRT-PCR. Graphs show a representative experiment of two with the mean value (± standard deviation) o triplicate amplification.
Fig. 14. TrxR1 protein expression in undiferenciated Caco-2/TC7 cells under 2.65 μM
[Au(C CPh)(PTA)] treatment. [Au(C ≡ CPh)(PTA)] treatment induces TrxR1 over-
expression. TrxR1 protein was quantified by flow cytometry. Results are expressed as
arbitrary fluoresce units.
mechanism are activated, ending this process with the death of the tu-
mour cell.
4. Conclusions
In conclusion we have demonstrated a slight lipophilic charac-
ter, chemical stability in buffered solution and good anticancer activ-
ity in the previously reported gold(I) alkynyl [Au(C CPh)(PTA)].
The main disadvantage of lipophilic drugs resides in the complica-
tions for their administration and blood transport. However in our case
this difficulties lack of importance to some extent, since [Au(C
CPh)(PTA)] can bind to BSA through hydrophobic interaction, en-
abling its transport in the blood.
On the other hand, in vitro assays demonstrated a high antiprolif-
erative activity of [Au(C CPh)(PTA)], which seems to be selective
for cancer cells. This cytotoxicity is caused by the inhibition of se-
lenoproteins such as Thioredoxin Reductase 1. The inhibition of this
enzyme produces an increase in ROS levels which induce apoptosis
directly – by targeting mPTP and inducing MPT that results in a dis-
sipation of MMP and release of cytochrome c – and indirectly by al-
tering the balance between pro-apoptotic and anti-apoptotic proteins.
Both pathways end in the activation of caspase 9, caspase 3 and ex-
ecution of apoptosis. Another consequence is a reduction in cell pro-
liferation which also promotes changes in the cell cycle such as a de
crease of events in G2. However, unlike cisplatin, [Au(C
CPh)(PTA)] does not interact with nucleic acids –DNA or RNA–, re-
ducing the risk of producing genomic mutations and hence decreasing
the side effects of anti-tumoral therapy.
All the obtained results predict a promising future for [Au(C
CPh)(PTA)] as a chemotherapeutic agent for CRC, nevertheless, fur-
ther studies should be done in this field. For instance, [Au(C
CPh)(PTA)] pharmacodynamics needs to be deeply addressed, as well
as the [Au(C CPh)(PTA)] anti-proliferative activity in 3D cultures
and in vivo models. Finally, the capacity of [Au(C CPh)(PTA)] to
target other selenoproteins should be studied. Nevertheless, this study
provides the first evidences to demonstrate that [Au(C CPh)(PTA)]
induce apoptosis, nor necrosis, in CRC cells by altering redox balance.
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